Gram Research analysis shows that milk thistle supplement increases how much resmetirom stays in the body by 37 percent and makes the drug work better at treating fatty liver disease in animal studies. When rats received both milk thistle and resmetirom together, their liver improved more than with either treatment alone, with better enzyme levels, cholesterol, and tissue healing. However, this preclinical research in rats needs human testing before doctors can recommend combining these treatments.
Researchers studied whether milk thistle, a popular supplement people take for liver health, affects how the body processes resmetirom, a new medication for fatty liver disease. Using rats with liver damage similar to human disease, scientists found that milk thistle increased how much resmetirom stayed in the body and made the drug work better. When rats took both together, their liver improved more than with either treatment alone. This suggests milk thistle and resmetirom might work well as a team, but people should talk to their doctors before combining them.
Key Statistics
A 2026 preclinical study in rats with fatty liver disease found that milk thistle supplement increased resmetirom blood exposure by 37 percent and reduced the body’s ability to clear the drug by 25 percent.
In laboratory tests using rat liver tissue, milk thistle extract extended resmetirom’s half-life from 331 minutes to 3,914 minutes, demonstrating a significant metabolism-mediated interaction at the cellular level.
Rats receiving both milk thistle and resmetirom together showed greater improvements in liver enzymes, cholesterol levels, and liver tissue appearance compared to either treatment alone in the 8-day study.
The Quick Take
- What they studied: Whether taking milk thistle supplement at the same time as resmetirom (a new liver disease medicine) changes how the body processes the drug and whether it makes the treatment work better.
- Who participated: Male laboratory rats that were given a special diet to create fatty liver disease similar to what happens in humans. The rats were divided into groups receiving different treatments for 8 days.
- Key finding: Milk thistle increased the amount of resmetirom in the bloodstream by 37 percent and made the drug stay in the body longer, which led to better improvements in liver health markers compared to using either treatment alone.
- What it means for you: If you take resmetirom for liver disease and also use milk thistle supplements, they may work together more powerfully than expected. This is promising but still needs human testing. Always tell your doctor about all supplements you take, especially when starting new medications.
The Research Details
Scientists used male laboratory rats that had been fed a special diet lacking methionine and choline, two nutrients that cause fatty liver disease similar to what humans develop. This model accurately mimics the human condition called metabolic dysfunction-associated steatohepatitis, or MASH. The rats were divided into four groups: one received no treatment, one received only resmetirom (the new liver drug), one received only milk thistle supplement, and one received both treatments together. All treatments lasted 8 days. Researchers measured drug levels in the blood using a precise laboratory technique called LC-MS/MS, which can detect tiny amounts of medication. They also studied how liver cells break down the drug by testing liver tissue samples in test tubes.
Understanding how supplements interact with medications is crucial because many people take both without realizing they might affect each other. This study used a well-established animal model of liver disease that closely resembles human MASH, making the findings more relevant to real patients. By measuring drug levels in both whole animals and isolated liver cells, researchers could pinpoint exactly where and how milk thistle changes the drug’s behavior in the body.
This is a preclinical study, meaning it was done in animals before any human testing. The researchers used validated scientific methods to measure drug levels and studied liver tissue samples in controlled laboratory conditions. However, animal studies don’t always translate directly to humans because our bodies work differently. The study was published in Biochemical Pharmacology, a respected scientific journal. The findings are promising but represent an early stage of research that needs human clinical trials to confirm the results apply to people.
What the Results Show
When rats received milk thistle along with resmetirom, the peak amount of drug in their blood increased by 17 percent. More importantly, the total amount of drug exposure over time increased by 37 percent, meaning the drug stayed active in the body much longer. The body’s ability to clear the drug decreased by 25 percent. In laboratory tests using liver tissue, milk thistle extract dramatically slowed how quickly liver cells broke down resmetirom, increasing the drug’s half-life from about 331 minutes to nearly 3,914 minutes. This means the drug lingered in liver cells much longer when milk thistle was present. The combination treatment produced the best results: rats showed greater improvements in liver enzyme levels, bilirubin (a marker of liver function), cholesterol and triglycerides, liver size, weight recovery, and overall liver tissue appearance compared to either treatment alone.
The study revealed that milk thistle’s active compounds, called silybin A and B, directly interfere with the liver’s ability to eliminate resmetirom. This interaction happens at the cellular level in liver tissue. The enhanced pharmacological response (meaning the drug worked better) when combined with milk thistle suggests the two treatments may have complementary effects on liver health. The improved liver histology, or tissue appearance, indicates that the combination reduced inflammation and fat accumulation more effectively than single treatments.
This is among the first studies examining the specific interaction between milk thistle and resmetirom. Previous research has shown that milk thistle can affect how the body processes other medications by interfering with liver enzymes responsible for drug breakdown. This study confirms that pattern applies to resmetirom. The findings align with earlier observations that milk thistle has hepatoprotective, or liver-protective, properties, but now show these properties may enhance rather than interfere with modern liver medications.
This study was conducted only in rats, not humans, so results may not directly apply to people. The researchers did not test different doses of milk thistle or resmetirom to see if the interaction changes at higher or lower amounts. The study lasted only 8 days, so long-term effects remain unknown. The specific type and concentration of milk thistle supplement used in the study may differ from commercial products available to consumers. Individual responses to the combination may vary based on genetics, diet, and other medications. This preclinical evidence needs to be followed by human clinical trials before doctors can make definitive recommendations about combining these treatments.
The Bottom Line
Based on this preclinical evidence, the combination of milk thistle and resmetirom appears promising for treating fatty liver disease and may produce better results than either treatment alone. However, this research was conducted in animals only. Confidence level: Low to Moderate for human application. People currently taking resmetirom should not start milk thistle without consulting their doctor, as the increased drug exposure might require dose adjustments. Conversely, people already taking milk thistle who begin resmetirom should inform their healthcare provider about the supplement so appropriate monitoring can occur.
This research is most relevant to people with metabolic dysfunction-associated steatohepatitis (MASH) or fatty liver disease who are considering or currently taking resmetirom. Patients interested in combining resmetirom with milk thistle supplements should discuss this with their hepatologist or primary care doctor. Healthcare providers prescribing resmetirom should ask patients about milk thistle and other supplement use. People with liver disease who take multiple medications should be aware that supplements can interact with prescription drugs. This research is less immediately relevant to people without liver disease or those not taking resmetirom.
In the rat study, improvements in liver markers and tissue appearance occurred within 8 days of combined treatment. In humans, if this interaction is confirmed, benefits would likely develop over weeks to months, similar to typical medication timelines. However, because the drug stays in the body longer when combined with milk thistle, any side effects might also be more pronounced or longer-lasting. Realistic expectations should include waiting for human clinical trials before expecting this combination to become standard treatment.
Frequently Asked Questions
Can I take milk thistle with resmetirom for liver disease?
Research in rats shows milk thistle increases resmetirom levels in the body by 37 percent, potentially making it work better but also requiring doctor monitoring. Talk to your doctor before combining them, as your dose may need adjustment based on this interaction.
Does milk thistle interfere with liver medications?
This study found milk thistle actually enhances resmetirom’s effects rather than interfering with it. However, milk thistle can affect how your liver processes other drugs, so always inform your doctor about supplements you take alongside any prescription medication.
What is resmetirom used for?
Resmetirom is a newer medication designed specifically to treat metabolic dysfunction-associated steatohepatitis, commonly called MASH or fatty liver disease. It works by activating thyroid hormone receptors in the liver to reduce fat accumulation and inflammation.
How long does it take to see improvements from combining these treatments?
In the rat study, improvements in liver markers appeared within 8 days. In humans, if this combination is eventually approved, benefits would likely develop over weeks to months, similar to how most liver medications work.
Is this study proof that milk thistle and resmetirom work well together in humans?
No, this is preclinical research in rats only. While promising, it requires human clinical trials before doctors can recommend this combination. Animal studies often don’t translate directly to people, so more research is needed.
Want to Apply This Research?
- Track liver enzyme levels (ALT, AST, bilirubin) monthly if taking resmetirom with milk thistle, recording the specific values and dates to monitor whether the combination is improving liver function as expected.
- Log all supplements taken daily in the app, specifically noting milk thistle dose and timing relative to resmetirom doses, to help your healthcare provider monitor for any unexpected effects from the combination.
- Set up monthly reminders to record liver function test results and any symptoms like fatigue, abdominal discomfort, or changes in appetite. Create a trend chart showing how these markers change over time to share with your doctor during appointments.
This article summarizes preclinical research conducted in animals and does not constitute medical advice. Resmetirom is a prescription medication that should only be used under direct medical supervision. Milk thistle is a dietary supplement not regulated by the FDA with the same rigor as medications. Do not start, stop, or change the dose of any medication or supplement without consulting your doctor or hepatologist. This research has not been tested in humans. Individual responses to treatments vary based on genetics, overall health, and other medications. If you have liver disease or are taking resmetirom, discuss all supplements with your healthcare provider before use. This article is for educational purposes only and should not replace professional medical consultation.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.